However, another Phase II clinical trial involving 80 ALS patients receiving rasagiline (2 mg/day for 12 months) did not demonstrate improvements in mitochondrial and molecular biomarkers (ΔΨm, ORAC, and Bcl-2/Bax ratio) or differences in the average 12-month ALSFRS-R slope between the rasagiline and placebo groups. This evidence concerns the gene BAX and amyotrophic lateral sclerosis.